Nanoparticles for direct nose-to-brain drug delivery: Implications of targeting approaches
Direct Nose-to-Brain Drug Delivery, Page: 157-168
2021
- 2Citations
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The use of nanocarriers for pharmaceutical and clinical applications is a well-established archetype since long time. These nanoparticulate carriers are expected to stay in blood for long time, accumulate at target site in desired extent, and facilitate the targeted drug delivery via target-specific drug-ligand complexes or conjugates in poorly reachable regions of the body. Talking more specifically about brain targeting, the highly dense blood-brain barrier (BBB) restricts the entry of variety of small and macromolecules to the brain regions, thereby put a great challenge to treat central nervous system (CNS) disorders. This fact urges the need of BBB-bypass drug delivery approach, so called direct nose-to-brain drug delivery. In order to improve the therapeutic effectiveness, the delivery strategies are focused on using the nanoparticulate carriers to conquer the BBB and directly targeting the diseased cells in the brain. This review entry highlights the various types of targeting strategies developed for direct nose-to-brain delivery using nanoparticles (NPs) as neurotherapeutic carriers. We hope this chapter containing comprehensive study reports would be a unique cluster of evidences for researchers exploring the direct nose-to-brain targeted drug delivery and would certainly benefit the physicians in improving the therapy for CNS disorders.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780128225226000084; http://dx.doi.org/10.1016/b978-0-12-822522-6.00008-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85128082980&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780128225226000084; https://dx.doi.org/10.1016/b978-0-12-822522-6.00008-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know